Closely-held Upswing Health, a virtual orthopedic company, is reinventing orthopedic care delivery through its virtual orthopedic musculoskeletal symptom assessment tool and customized pain management program...

Closely-held Intrinsic medicine is developing new drugs for diseases that are linked to the disordered interaction of the gut microbiome, the immune system and the nervous system.

Closely-held Rainhouse Manufacturing, a company specializing in computer numerical control (CNC) machining, quality assurance, and electronic manufacturing, is working with companies to make their medical device designs...

Closely-held Hygieia, a digital therapeutics company for insulin therapy, is reforming how physicians and people with type 2 diabetes manage insulin with its breakthrough proprietary mobile app, d-Nav, which...

Closely-held Jeeva Informatics has developed a centralized electronic clinical platform that aims to help clinical trial sponsors increase the efficiency of their clinical trials, while expanding trial access to...

Closely-held EndoGlow, a medical device company, is revolutionizing minimally invasive surgery and improving patient outcomes by enhancing visualization through its proprietary Tissue Reveal Technology (TRT), a polymer...

Closely-held Glyscend Therapeutics is developing an orally administered, gut-restricted drug for Type 2 diabetes and obesity, based on “duodenal exclusion” physiology, a key mechanism of gastric bypass surgery.

Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential to improve the lives of patients with inflammatory disorders and...

Closely-held ImmunoBrain Checkpoint, with its R&D team in Israel, is pursuing a unique approach that targets the peripheral immune system, rather than directly targeting the brain in patients suffering from Alzheimer’s...

Monogram Orthopedics (NASDAQ:MGRM) is working to advance the standard of care with its next-generation robot and 3D-printed implants that match a patient's precise anatomy, decreasing the number of incisions and bone...

Closely-held Cantex Pharmaceuticals has an extensive Phase 2 program underway with its lead drug candidate, azeliragon, in breast cancer, pancreatic cancer, brain metastasis and glioblastoma, well as in prevention of...